Getting to a successful retirement on one’s terms is the No. 1 financial goal for many AAOMS members. Qualified retirement plans – such as pensions, profit-sharing plans and 401(k)s – are powerful tools to help achieve this goal. However, while popular, they are often misused by practices or implemented sub-optimally. Non-qualified plans can be even more powerful tools, yet few practices implement them. This 90-minute webinar explains the pros and cons of both at a high level with examples. With these tools and others, participants can figure out if they are on track for their retirement goals. Code: WPM230510

Register for this 2-part webinar series on Anesthesia and Medicine and save $50 off the original price of $250! Code: WCE23B02

Cannabis is the most popular illicit drug worldwide. While the DEA still classifies it as a Schedule I controlled substance, it is now legal in many states – with cannabis use still on the rise in the U.S. This increase is particularly seen in high school and college-age students. OMSs will likely encounter patients who use cannabis, affecting the administration and effects of anesthesia – including local anesthesia, nitrous oxide and intravenous sedation/anesthesia. It is important for OMSs to understand how to manage patients who use cannabis. During this 60-minute webinar, participants will learn the pharmacologic and physiologic effects of cannabis, different intake methods and how cannabis can affect office-based anesthesia. Code: WCE230712

In recent years, there has been a growing interest in the use of psychedelic substances as a potential treatment option for a variety of medical conditions. Regulatory restrictions on research into psychedelics were lifted in 2000, and the first landmark study on psilocybin at Johns Hopkins University was published in 2006. The volume of research has been growing every year. Psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and methylenedioxymethamphetamine (MDMA) have been shown in clinical trials to be effective in treating conditions such as depression, anxiety, PTSD, addiction and end-of-life distress. In recent years, several cities such as Detroit, Seattle and Santa Cruz as well as all of Oregon and Colorado have decriminalized the possession and use of psychedelic substances. The FDA has granted breakthrough therapy designation for psilocybin and MDMA-assisted therapy for certain conditions. As legislation changes and psychedelics move from the underground to the mainstream, the anesthetic, dental and oral and maxillofacial surgery fields will have to adjust. This 60-minute webinar will define psychedelics and explore the risks, benefits and potential place in dentistry and oral and maxillofacial surgery. Code: WCE230726